The short answer
Different parent molecules, different primary research focus.
Selank is a synthetic analog of tuftsin, an immune-system peptide. Published clinical research from Zozulia and colleagues (2008) and mechanistic work by Vyunova and colleagues (2018) describe Selank primarily in the context of anxiolytic (anti-anxiety) effects, including modulation of GABA-receptor binding. Semax is a synthetic analog of ACTH(4-10), a fragment of adrenocorticotropic hormone. Research by Dolotov and colleagues (2003, 2006) describes Semax primarily in connection with increased expression of brain-derived neurotrophic factor (BDNF) in rat brain tissue — a neurotrophic, cognitive-research focus distinct from Selank's anxiolytic literature.
Classification comparison
| Attribute | Selank | Semax |
|---|---|---|
| Parent molecule | Tuftsin (immune peptide) analog | ACTH(4-10) fragment analog |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular weight | 751.9 g/mol | ~751 g/mol (heptapeptide) |
| Primary studied context | Anxiolytic effects, GABA-receptor modulation | BDNF/NGF expression, cognitive & neuroprotective research |
| Origin | Developed in Russia; clinical use history there | Developed in Russia; clinical use history there |
| DAAVY listing | Selank 10 mg · COA8114 — Semax is not currently sold by DAAVY Research | |
What published research has studied
A 2008 open clinical study by Zozulia and colleagues, published in Zhurnal Nevrologii i Psikhiatrii, compared Selank to the benzodiazepine medazepam in 62 patients with generalized anxiety disorder and neurasthenia, reporting broadly comparable anxiolytic effects between the two along with additional anti-asthenic effects attributed to Selank. A 2018 mechanistic review by Vyunova and colleagues in Current Medicinal Chemistry reported that Selank acts as a positive allosteric modulator of GABA receptor binding in laboratory assays, proposing this as one possible basis for its studied anxiolytic activity.
Semax's research base centers on neurotrophin signaling. Dolotov and colleagues reported in a 2003 paper (Doklady Biological Sciences) that Semax stimulated BDNF expression across multiple rat brain regions in vivo, and in a follow-up 2006 study (Journal of Neurochemistry) demonstrated specific, reversible binding of labeled Semax to rat basal forebrain tissue alongside increased BDNF protein levels following intranasal application. This neurotrophic mechanism is the basis for Semax's use in Russian cognitive and neuroprotective research contexts.
What this research does not establish
- Neither compound is FDA-approved. Both have a clinical use history in Russia that has not been replicated in large, independent, placebo-controlled Western trials.
- The Selank clinical literature is small and largely from one research group. The cited 2008 study involved 62 patients and originated from the same institutes that developed the compound.
- Most Semax neurotrophin data comes from rodent studies, not human trials — the BDNF/NGF findings referenced above are from rat brain tissue.
- No published research directly compares Selank and Semax head-to-head in the same trial; this page synthesizes separate literatures on each compound, not a comparative study.
- Neither has an established human dosing or long-term safety profile outside the specific Russian clinical contexts referenced in the cited sources.
Reading the documentation
Since DAAVY Research sells Selank, its current listing includes a Certificate of Analysis confirming identity (LC-MS/MS), content relative to the labeled amount (HPLC quantitation), and overall purity (RP-HPLC). See the current Selank 10 mg listing for COA8114, or the full COA guide for the general checklist. DAAVY Research does not currently sell Semax and cannot speak to any third-party Semax COA.
Sources
- Zozulia et al. (2008), "Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia," Zhurnal Nevrologii i Psikhiatrii — PubMed
- Vyunova et al. (2018), "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity," Current Medicinal Chemistry — PubMed
- Dolotov et al. (2003), "The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo," Doklady Biological Sciences — PubMed
- Dolotov et al. (2006), "Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain," Journal of Neurochemistry — PubMed
Research-use disclaimer
This page summarizes published research findings for informational and research-identification purposes only. It does not describe, recommend, or endorse any human or veterinary use, dosing, or health outcome. DAAVY Research supplies Selank strictly for legitimate laboratory, academic, institutional, or qualified independent research and does not sell Semax.
Frequently asked questions
What's the main studied difference between Selank and Semax?
Selank is studied primarily for anxiolytic effects and GABA-receptor modulation; Semax is studied primarily for BDNF/NGF neurotrophic signaling in cognitive research contexts.
Does DAAVY Research sell Semax?
No. DAAVY Research sells Selank. Semax is covered here for comparison and research-identification purposes only.
Is either compound approved for human use in the United States?
No. Neither is FDA-approved; both have a clinical history in Russia that hasn't been replicated in large independent Western trials.